Alle Storys
Folgen
Keine Story von Dr. Hönle AG mehr verpassen.

Dr. Hönle AG

euro adhoc: Dr. Hönle AG
Financial Figures/Balance Sheet
Hönle presents figures for the first quarter

  Disclosure announcement transmitted by euro adhoc. The issuer is responsible
  for the content of this announcement.
25.02.2009
The economic situation deteriorated noticeably in the first quarter 
of the 2008/2009 financial year. All regions and many industries are 
affected by this development and new orders declined significantly in
the printing industry, in particular. Hönle was also not exempted 
from this negative economic development. Sales revenues of the Hönle 
Group increased by 75.1 % to TEUR 12,751 in the first quarter of the 
financial year in comparison with the previous year as a result of 
acquisitions but declined by 19.6 % in comparison with the previous 
year´s quarter. Earnings before interest and tax (EBIT) dropped from 
TEUR 1,381 in the previous year to TEUR -592 in the first quarter of 
the current financial year. Earnings before tax (EBT) declined from 
TEUR 1,562 to TEUR -594 and the Group´s result decreased from TEUR 
1,147 to TEUR -580. Earnings per share dropped from EUR 0.20 to EUR 
-0.11.
Liquid assets, securities and own shares amount to TEUR 10,824. The 
equity capital ratio is 67.4 %.
Outlook: The restrained investment behaviour, which can be observed 
in many sectors, will also impact on Hönle Group´s business 
development. However, at present it is almost impossible to forecast 
the extent and duration of the restrained investing behaviour, in 
particular in the printing industry. In February, the Hönle Group 
further extended short-time working in order to adjust manufacturing 
capacities to the decline in incoming orders. At present, about 35 % 
of the workforce is affected by short-time working.
Following the acquisition of several companies, integrating the new 
companies into the Hönle Group will be given priority in the new 
financial year. The main objective is to save costs by expanding the 
output chain and by centralising certain functions such as joint 
purchasing activities. The cost reduction program includes short-term
as well as long-term measures. Manufacture of the Eltosch systems, 
which to date has been outsourced to external suppliers, will be 
transferred to Dr. Hönle AG in the course of this financial year. 
Production will then be combined and Eltosch und Hönle systems will 
be produced at one joint site which is both efficient and cost 
saving. Panacol and Wellomer will move to new company premises which 
they will use jointly. The production processes of these companies 
will also be combined to enable more efficient and cost-saving 
manufacture. Moreover, R&D capacities can be utilised more 
efficiently.
Savings in Purchasing will improve the cost situation. Materials 
procurement in plant engineering and in the adhesives segment will be
centralised within the Hönle Group, which will optimise purchasing 
conditions.
Overall, the Board of Management is convinced that UV technology will
continue to grow in popularity despite the present economic 
situation. Due to the advantages of UV technology in comparison with 
conventional drying and curing processes, its popularity and use in 
new fields will increase. Following the corporate acquisitions, the 
Hönle Group has positioned itself strongly in a very interesting 
market environment: It is now the second largest systems supplier 
worldwide in the market for industrial UV technology. Hönle is thus 
well equipped to overcome a period of economic weakness and to emerge
stronger from the financial crisis. The restructuring measures 
initiated will see Hönle better positioned than ever for future 
profitable growth after the presently restrained investing behaviour 
has come to an end.
end of announcement                               euro adhoc

Further inquiry note:

Dr. Hönle AG, Peter Weinert, Lochhamer Schlag 1, 82166 Gräfelfing/Munich, Tel.:
089-85608-173, Fax: 089-85608-148, ir@hoenle.de, www.hoenle.de

Branche: Instrument Engineering
ISIN: DE0005157101
WKN: 515710
Index: CDAX, Prime All Share, Technologie All Share
Börsen: Börse Frankfurt / regulated dealing/prime standard
Börse Berlin / free trade
Börse Hamburg / free trade
Börse Stuttgart / free trade
Börse Düsseldorf / free trade
Börse Hannover / free trade
Börse München / free trade

Weitere Storys: Dr. Hönle AG
Weitere Storys: Dr. Hönle AG
  • 14.08.2008 – 06:06

    Hönle reports sharp rise in sales revenue and profit

    ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement. companies Gräfeling/München (euro adhoc) - The Hönle Group´s sales revenue in the first nine months of the current financial year increased by 72.6 % to TEUR 32,887. At the same time, the operating result (EBIT) improved by 60.0 % to TEUR 4,808, while earnings before taxes (EBT) increased by 41.3 % ...

  • 15.05.2008 – 06:24

    Hönle Increases Net Income by 90 %

    ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement. finances Gräfeling/München (euro adhoc) - The revenue of the Hönle Group increased in the first half year by 41.2 % to 18,036 TEUR. The Earnings before interest and taxes (EBIT) rose by 64.5 % to 3,416 TEUR. Earnings before taxes (EBT) climbed by 53.7 % to 3,702 TEUR. Net income rose even more ...